Sevelamer, Fetuin-A and Endothelial Dysfunction in CKD
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Vascular calcification and endothelial dysfunction (ED) contribute to the development of
cardiovascular disease (CVD) in patients with chronic kidney disease (CKD). Sevelamer, a
non-calcium based phosphate binder, has been shown to attenuate cardiovascular calcification
in CKD patients while the exact mechanism has not been clarified.
This study was designed to investigate the effect of short-term sevelamer treatment on both
serum fetuin-A concentrations and ED seen in CKD patients.